---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-010190"
form_type: "8-K"
ticker: "TLPH"
cik: "0001427925"
company_name: "TALPHERA, INC."
filed_at: "2025-03-31T23:59:59+00:00"
generated_at: "2026-05-24T01:40:30.643121+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Talphera reports Q4 2024 net loss $1.9M; FDA cuts NEPHRO study size to 70 patients

## Summary
- FDA agreed to reduce NEPHRO CRRT study from 166 to 70 patients; study completion targeted by end of 2025.
- Cash and investments of $8.9M at Dec 31, 2024; additional $14.8M private placement financing announced.
- Q4 2024 net loss from continuing operations $1.9M ($0.07 per share) vs $4.5M ($0.25) in Q4 2023.
- Combined R&D and SG&A expenses decreased to $3.0M in Q4 2024 from $4.6M in Q4 2023.
- 2025 cash operating expense guidance of $18M-$19M, includes costs to complete NEPHRO study.

## SEC filing metadata
- accession: 0001437749-25-010190
- form_type: 8-K
- ticker: TLPH
- cik: 0001427925
- company_name: TALPHERA, INC.
- filed_at: 2025-03-31T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/0001437749-25-010190-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1427925/000143774925010190/acrx20250330_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-010190
- JSON: https://secwatch.observer/filing/0001437749-25-010190.json
- Plain text: https://secwatch.observer/filing/0001437749-25-010190.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.